Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574138 | 1.00 | ADORA3 (0.39) | ADORA3PDE7ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20991112 | 1.00 | ADORA3 (0.39) | ADORA3PDE7ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20469074 | 1.00 | ADORA3 (0.39) | ADORA3PDE7ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21834171 | 0.94 | ADORA3 (0.36) | ADORA3 | |
| SCHEMBL29752687 | 0.94 | ADORA3 (0.36) | ADORA3 | |
| SCHEMBL9364337 | 0.90 | ADORA3 (0.34) | ADORA3 | |
| SCHEMBL30068180 | 0.90 | ADORA3 (0.34) | ADORA3 | |
| SCHEMBL25169501 | 0.84 | ADORA3 (0.32) | ADORA3 | |
| SCHEMBL30921586 | 0.84 | ADORA3 (0.32) | ADORA3 | |
| SCHEMBL1383352 | 0.81 | OPRM1 (0.38) | ADORA3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109996792-B | Heterocyclic compounds having activity as modulators of muscarinic M1 and/or M4 receptors in the treatment of CNS diseases and pain | 赫普泰雅治疗有限公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-2385947-A1 | TIME TEMPERATURE INDICATOR COMPRISING INDOLENIN BASED SPIROPYRANS | BASF SE (DE) | 2011-11-16 | — | — | EP | disclosed |
| EP-1750704-B1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7550499-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1750704-A2 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | Bristol-Myers Squibb Company (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005113537-A2 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050261244-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261244-A1 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | P2RY1, P2RY11, P2RY2 | ADORA3 48/4885PDE7A 148/4885SLC6A2 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.